MDLNMedline Inc.
Price
End-of-day closes, not the intraday tick.
More going right than wrong
No red flags, price roughly fair, the market undecided.
Medline Inc. is a holding company and its only material assets are its equity interests held directly or indirectly through wholly owned subsidiaries in Medline Holdings, and it is accordingly dependent upon distributions from Medline Holdings to pay taxes, make payments under the tax receivable agreement, and pay any dividends. Medline Inc. is a holding company with no material assets other than its ownership of Common Units held directly or indirectly through wholly owned subsidiaries.
In the company’s own words · 10-K filed Feb 25, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Medline Inc. (MDLN) reported revenue of $7.68B in Q2 2026 (quarter ended Jun 27, 2026), up 16% from the same quarter a year earlier. That came with a gross margin of 29% and net income of $139M (1.8% of revenue). For the full year FY2025, revenue was $28.4B (+11% year on year) and net income $1.16B. Its largest product in Q2 2026 was Acute Care at $5.41B, 73% of the disclosed total, well ahead of Non Acute Care at 24%. The next results filing is expected around Nov 4, 2026, a quarter after the last one.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 15, 2026On October 13, 2026, Joseph P. Baratta notified the Board of Directors (the “Board”) of Medline Inc. (the “Company”) of his decision to resign from the Board, effective as of December 31, 2026.Director or officer change · Form 8-K
- Aug 5, 2026Medline Reports Second Quarter and.Earnings release · press release
- Jul 9, 2026On July 7, 2026, Stephen L. Miller, Chief Operating Officer of Medline Inc. (the “Company”), notified the Company that he would retire from his role, effective August 30, 2026, for health-related reasons.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $7.40BThe company’s own SEC segment disclosure.
- Acute Care$5.41B73%
- Non Acute Care$1.75B24%
- Laboratory And Diagnostics$248.0M3%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Medical Instruments & Supplies
The closest names by size in the same industry